Vasopressin V1B Receptor Antagonists as Potential Antidepressants
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V1B receptor) play a pivotal role in HPA axis abnormalities observed in depression. Based on this hypothesis, several non-peptide V1B receptor antagonists have been synthesized, and the efficacies of some V1B receptor antagonists have been investigated in both animals and humans. V1B receptor antagonists exert antidepressant-like effects in several animal models at doses that attenuate the hyperactivity of the HPA axis, and some of their detailed mechanisms have been delineated. These results obtained in animal models were, at least partly, reproduced in clinical trials. At least 2 V1B receptor antagonists (TS-121 and ABT-436) showed tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1B receptor. Importantly, TS-121 showed a clearer efficacy for patients with higher basal cortisol levels than for those with lower basal cortisol levels, which was consistent with the hypothesis that V1B receptor antagonists may be more effective for patients with HPA axis hyperactivity. Therefore, V1B receptor antagonists are promising approaches for the treatment of depression involving HPA axis impairment such as depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Carroll, B. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780260017001 · Cited by 2,243
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Stetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 1×
“…of the hypothalamus-pituitary-adrenal (HPA) axis is generally acknowledged to occur in a subset of MDD patients (Dinan and Scott, 2005; Stetler and Miller, 2011), and patients with treatment-resistant depression or severe depression tend to show HPA axis dysfunction (Juruena et al., 2009;…”
BackgroundBessa, J. M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J. J., Palha, J. A., Almeida, O. F. X., & Sousa, N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.119 · Cited by 598
Surget, A., Saxe, M., Leman, S., Ibarguen-Vargas, Y., Chalon, S., Griebel, G., Hen, R., & Belzung, C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.022 · Cited by 556
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Regulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Thus far, the antidepressant effects of V1bR antagonists in small clinical trials are mixed but show efficacy signals in patients with overactive HPA activity (22) (Figure 2).”
BackgroundMikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
“Rodents in which AVP deficiency was observed exhibited reduced depressive and anxiety-like behavior [128].”
BackgroundMethodInfluentialNeuroinflammation—A Crucial Factor in the Pathophysiology of Depression—A Comprehensive Review
Sălcudean, A., Bodo, C.-R., Popovici, R. A., Lica, M. M., Păcurar, M., Crăciun, R.-E., Crișan, A., ENĂTESCU, V. R., Marinescu, I. P., Cîmpian, D. M., et al. (2025) · Biomolecules · doi:10.3390/biom15040502 · Cited by 197
“Conversely, NPY has been shown to exert anxiolytic effects and counteract the effects of stress on the HPA axis, exerting a protective role against stress-induced mood disorders [86,87].”
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“( A higher resolution/colour version of this figure is available in the electronic copy of the article ). blood-brain-barrier [84, 85].”
BackgroundThe cortisol axis and psychiatric disorders: an updated review
George, M. Y., Mageed, S. S. A., Mansour, D. E., & Fawzi, S. F. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00782-x · Cited by 100
“By antagonizing these receptors, V 1B receptor antagonists can potentially reduce cortisol secretion and normalize HPA axis activity [ 135 ].”
The Role of Inflammation in the Pathophysiology of Depression and Suicidal Behavior
Serafini, G., Costanza, A., Aguglia, A., Amerio, A., Trabucco, A., Escelsior, A., Sher, L., & Amore, M. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.09.001 · Cited by 56
Kanes, S., Dennie, L., & Perera, P. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s402831 · Cited by 31
“In animal models, antagonism of the V1b receptor has been shown to attenuate depressive-like and anxiety-like behaviors, particularly in stressful situations.(6,153) For example, the Brattleboro rat strain, which is characterized by a spontaneous AVP deficiency caused by a single nucleotide deletion in the AVP gene, e…”
BackgroundMethodResultInfluentialClass A and C GPCR Dimers in Neurodegenerative Diseases
Moreira, I. S., Caniceiro, A. B., Bueschbell, B., & Schiedel, A. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327221830 · Cited by 20
Hu, H., Zarate, C. A., & Verbalis, J. G. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13703 · Cited by 20
“22 This is particularly important for HPA axis adaptation to chronic stress conditions, especially in maintaining basal secretion of glucocorticoids, as well as in maintaining ACTH-responsiveness when a novel stressor is introduced under chronic stress conditions.”
InfluentialArginine Vasopressin, Synaptic Plasticity, and Brain Networks
Winklewski, P. J., Marcinkowska, A. B., & Biancardi, V. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220222143532 · Cited by 19
Fulenwider, H. D., Zhang, Y., & Ryabinin, A. E. (2023) · Hormones and Behavior · doi:10.1016/j.yhbeh.2023.105452 · Cited by 18
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder
László, K., Vörös, D., Correia, P., Fazekas, C. L., Török, B., Plangár, I., & Zelena, D. (2023) · Biomedicines · doi:10.3390/biomedicines11102603 · Cited by 13
Vasopressin receptor antagonists: a patent summary (2018-2022)
Baska, F., Bozó, É., & Patócs, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2218546 · Cited by 11
Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression
Guan, W., Wang, Q., & Sheng, X.-M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116672 · Cited by 10
Holsboer, F., & Ising, M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2372-3549 · Cited by 9
“To date, eight non - peptidergic chemical molecules that selectively block V1b-receptors after oral administration were thoroughly studied in preclinical ex - periments and provided encouraging results (see reviews: [90, 91]).”
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work
Milo, T., Halber, S. N., Raz, M., Danan, D., Mayo, A., & Alon, U. S. (2025) · Molecular Systems Biology · doi:10.1038/s44320-024-00083-0 · Cited by 8
“Accordingly, V1bR antagonists did not show statistically signi fi cant ef fi cacy in clinical trials for major depressive disorder and generalized anxiety disorder (Griebel et al, 2012; Chaki, 2021; Kamiya et al, 2020).”
Epigenetic Modulation of Vasopressin Expression in Health and Disease
Török, B., Fazekas, C. L., Szabó, A., & Zelena, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179415 · Cited by 7
“However, further drug development is still ongoing and recent clinical outcomes with at least two ot er V1b antagonists (TS-121 and ABT-436) are promising, sh wing tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary…”
BackgroundMelanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics
Chaki, S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173818 · Cited by 6
Self-citationSiddiqui, S. H., Komnenov, D., Olayonwa, A., & Rossi, N. F. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70105 · Cited by 3
Hu, H., Lee, Y., Tillman, A. N., Ballard, E. D., Waldman, L. R., Yuan, P., Johnston, J. N., Peng, S., Kvarta, M. D., Verbalis, J. G., et al. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70133 · Cited by 3
“11,12 Prior studies that measured AVP in biological samples (i.e., plasma, saliva, and less commonly, cerebrospinal fluid) drawn from individuals with mood and trauma-related disorders yielded mixed results.”
Tregeagle, D. F. L., Doherty, C., Callis, T. B., & Kassiou, M. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.04.004 · Cited by 3
Psychoendocrinology: arginine vasopressin and resilience in patients with major depressive disorder
Mawella, S. M. A., Hussein, H. A., Zyada, F., Abdelaal, A., Ayoub, D. R., & Naguy, A. (2021) · CNS Spectrums · doi:10.1017/s1092852921000730 · Cited by 4
“The scores range from 0 to 63, where higher scores indicate greater depression severity: (0-1) indicates no or minimal depression, (14-19) indicates mild depression, (20-28) indicates moderate depression, and (29-63) indicates severe depression.”
BackgroundDeuterated 1,3 Dihydro-2H-indole-2-one Derivatives for Treatment of Depression or Anxiety
Hu, Q.-L., & Liang, S. H. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00284 · Cited by 3
Neuropeptidergic systems in psychiatric disorders
Hodzic, S., & Riedemann, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1654292 · Cited by 2
Therapeutic potential of vasopressin in the treatment of neurological disorders
Mishra, S., Grewal, J., Wal, P., Bhivshet, G. U., Tripathi, A. K., & Walia, V. (2024) · Peptides · doi:10.1016/j.peptides.2024.171166 · Cited by 5
Ślusarz, M. J. (2024) · Biopolymers · doi:10.1002/bip.23627 · Cited by 2
Трофимов, А. Н. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240205at · Cited by 1
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00006-5
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
zu Eulenburg, C., Gehrlach, D., Myhsok, M., Strote, C., Arvastson, L., Müller‐Myhsok, B., Griebel, G., & Eriksson, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1645225
Kim, H. K., & Woo, S. H. (2025) · Korean Intraoperative Neuromonitoring Society · doi:10.54441/jnn.2025.5.2.145
Antidépresseurs : aspects pharmacologiques
Chalah, M. A., & Gaillard, R. (2025) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(25)46993-4
Circuit logic of oxytocin and vasopressin complementary actions
Jeanneteau, F. D., Chakraborty, P., Petitjean, H., & Charlet, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1875731
“To this effect, combination therapy with OT analogs and VP antagonists (or other relevant peptides) is currently being assessed (Gupta and Prabhavalkar, 2021; Chaki, 2021).”
Weisenseel, Z., & Glasper, E. R. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101328
“In humans, chronic stress-related neuropsychiatric disorders are associated with dysregulation of AVP and V1bR signaling, and V1bR antagonists have been proposed as potential therapeutic agents for disorders characterized by HPA axis hyperactivity (Caldwell et al., 2017; Chaki, 2021).”
Metadata
- Authors
- Chaki, S.
- Affiliations
- Taisho Pharmaceutical (Japan) (JP)
- Corresponding author
- Chaki, Shigeyuki
- ORCID
- Chaki, Shigeyuki
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-18
- Volume
- 24
- Issue
- 6
- Pages
- 450-463
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC8278797
- OpenAlex
- W3138981265
- Cited by
- 34
- References
- 95
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 3 · 2021: 3
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- depression, hypothalamic-pituitary-adrenal axis, vasopressin, major depressive disorder, basal cortisol, antidepressant efficacy, stress response
- MeSH terms
- Animals, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Receptors, Vasopressin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.